You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 34.227.0.0/16 has been blocked by ‪Blablubbs‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 11:46, 23 November 2025. Your current IP address is 34.227.114.28.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
This IP address range has been globally blocked.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

This block affects editing on all Wikimedia wikis.
The IP address or range 34.227.0.0/16 has been globally blocked by ‪Jon Kolbert‬ for the following reason(s):

Open proxy/Webhost: See the help page if you are affected

This block will expire on 05:38, 21 February 2029. Your current IP address is 34.227.114.28.

Even while globally blocked, you will usually still be able to edit pages on Meta-Wiki.

If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

Other useful links: Global blocks · Help:I have been blocked

You can view and copy the source of this page:

{| class="wikitable sortable mw-collapsible (({state<includeonly>|mw-collapsed</includeonly>))}" style="margin: 1em auto;"
|+ class="nowrap" | ((Navbar|Androgen replacement therapy formulations and dosages used in men|mini=y)) <noinclude>[[Androgen replacement therapy]]</noinclude><includeonly>Androgen replacement therapy</includeonly> formulations and dosages used in men
|-
! Route !! Medication !! Major brand names !! Form !! Dosage
|-
| rowspan="6" | [[Oral administration|Oral]] || ((No selflink|Testosterone (medication)|Testosterone))<sup>a</sup> || – || Tablet || 400–800&nbsp;mg/day (in divided doses)
|-
| ((No selflink|Testosterone undecanoate)) || Andriol, Jatenzo || Capsule || 40–80&nbsp;mg/2–4x day (with meals)
|-
| ((No selflink|Methyltestosterone))<sup>b</sup> || Android, Metandren, Testred || Tablet || 10–50&nbsp;mg/day
|-
| ((No selflink|Fluoxymesterone))<sup>b</sup> || Halotestin, Ora-Testryl, Ultandren || Tablet || 5–20&nbsp;mg/day
|-
| ((No selflink|Metandienone))<sup>b</sup> || Dianabol || Tablet || 5–15&nbsp;mg/day
|-
| ((No selflink|Mesterolone))<sup>b</sup> || Proviron || Tablet || 25–150&nbsp;mg/day
|-
| rowspan="2" | [[Sublingual administration|Sublingual]] || ((No selflink|Testosterone (medication)|Testosterone))<sup>b</sup> || Testoral || Tablet || 5–10&nbsp;mg 1–4x/day
|-
| ((No selflink|Methyltestosterone))<sup>b</sup> || Metandren, Oreton Methyl || Tablet || 10–30&nbsp;mg/day
|-
| rowspan="2" | [[Buccal administration|Buccal]] || ((No selflink|Testosterone (medication)|Testosterone)) || Striant || Tablet || 30&nbsp;mg 2x/day
|-
| ((No selflink|Methyltestosterone))<sup>b</sup> || Metandren, Oreton Methyl || Tablet || 5–25&nbsp;mg/day
|-| [[Intranasal administration|Intranasal]] || ((No selflink|Testosterone (medication)|Testosterone)) || Natesto || Nasal spray || 11&nbsp;mg 3x/day
|-
| rowspan="5" | [[Transdermal administration|Transdermal]] || rowspan="4" | ((No selflink|Testosterone (medication)|Testosterone)) || AndroGel, Testim, TestoGel || Gel || 25–125&nbsp;mg/day
|-
| Androderm, AndroPatch, TestoPatch || Non-scrotal patch || 2.5–15&nbsp;mg/day
|-
| Testoderm || Scrotal patch || 4–6&nbsp;mg/day
|-
| Axiron || Axillary solution || 30–120&nbsp;mg/day
|-
| ((No selflink|Androstanolone|Androstanolone (((Abbr|DHT|dihydrotestosterone))))) || Andractim || Gel || 100–250&nbsp;mg/day
|-
| [[Rectal administration|Rectal]] || ((No selflink|Testosterone (medication)|Testosterone)) || Rektandron, Testosteron<sup>b</sup> || Suppository || 40&nbsp;mg 2–3x/day
|-
| rowspan="10" | [[Injection (medicine)|Injection]] (((abbrlink|IM|intramuscular injection)) or ((abbrlink|SC|subcutaneous injection))) || ((No selflink|Testosterone (medication)|Testosterone)) || Andronaq, Sterotate, Virosterone || Aqueous suspension || 10–50&nbsp;mg 2–3x/week
|-
| ((No selflink|Testosterone propionate))<sup>b</sup> || Testoviron || Oil solution || 10–50&nbsp;mg 2–3x/week
|-
| rowspan="2" | ((No selflink|Testosterone enanthate)) || Delatestryl || Oil solution || 50–250&nbsp;mg 1x/1–4&nbsp;weeks
|-
| Xyosted || Auto-injector || 50–100&nbsp;mg 1x/week
|-
| ((No selflink|Testosterone cypionate)) || Depo-Testosterone || Oil solution || 50–250&nbsp;mg 1x/1–4&nbsp;weeks
|-
| ((No selflink|Testosterone isobutyrate)) || Agovirin Depot || Aqueous suspension || 50–100&nbsp;mg 1x/1–2&nbsp;weeks
|-
| ((No selflink|Testosterone phenylacetate))<sup>b</sup> || Perandren, Androject || Oil solution || 50–200&nbsp;mg 1x/3–5&nbsp;weeks
|-
<!--| ((No selflink|Testosterone hexahydrobenzoate))<sup>b</sup> || Testormon Depot || Oil solution || 25&nbsp;mg 1x/1–3&nbsp;days
|--->
| ((No selflink|Testosterone propionate/testosterone phenylpropionate/testosterone isocaproate/testosterone decanoate|Mixed testosterone esters)) || Sustanon 100, Sustanon 250 || Oil solution || 50–250&nbsp;mg 1x/2–4&nbsp;weeks
|-
| ((No selflink|Testosterone undecanoate)) || Aveed, Nebido || Oil solution || 750–1,000&nbsp;mg 1x/10–14&nbsp;weeks
|-
| ((No selflink|Testosterone buciclate))<sup>a</sup> || – || Aqueous suspension || 600–1,000&nbsp;mg 1x/12–20&nbsp;weeks
|-
| [[Subcutaneous implant|Implant]] || ((No selflink|Testosterone (medication)|Testosterone)) || Testopel || Pellet || 150–1,200&nbsp;mg/3–6&nbsp;months
|- class="sortbottom"
| colspan="5" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Notes:''' Men produce about 3 to 11&nbsp;mg testosterone per day (mean 7&nbsp;mg/day in young men). '''Footnotes:''' <sup>a</sup> = Never marketed. <sup>b</sup> = No longer used and/or no longer marketed. '''Sources:''' <noinclude><ref name="NieschlagBehre2012a">((cite book|author1=Eberhard Nieschlag|author2=Hermann M. Behre|title=Testosterone: Action - Deficiency - Substitution|url=https://books.google.com/books?id=jn3nCAAAQBAJ&pg=PA298|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-72185-4|pages=298–))</ref><ref name="NieschlagBehre2012b">((cite book|author1=Eberhard Nieschlag|author2=Hermann M. Behre|author3=Susan Nieschlag|title=Testosterone: Action, Deficiency, Substitution|url=https://books.google.com/books?id=MkrAPaQ4wJkC&pg=PA312|date=26 July 2012|publisher=Cambridge University Press|isbn=978-1-107-01290-5|pages=312–))</ref><ref name="NieschlagBehre2010">((cite book|author1=Eberhard Nieschlag|author2=Hermann M. Behre|author3=Susan Nieschlag|title=Andrology: Male Reproductive Health and Dysfunction|url=https://books.google.com/books?id=mEgckDNkonUC&pg=PA443|date=13 January 2010|publisher=Springer Science & Business Media|isbn=978-3-540-78355-8|pages=443–))</ref><ref name="ByrneNieschlag2017">((cite book|last1=Byrne|first1=M. M.|last2=Nieschlag|first2=E.|title=Encyclopedia of Hormones|chapter=Androgens: Pharmacological Use and Abuse|year=2017|doi=10.1016/B978-0-12-809324-5.03356-3))</ref><ref name="NieschlagBehre2013">((cite book|author1=Eberhard Nieschlag|author2=Hermann Behre|title=Andrology: Male Reproductive Health and Dysfunction|url=https://books.google.com/books?id=05fsCAAAQBAJ&pg=PA206|date=29 June 2013|publisher=Springer Science & Business Media|isbn=978-3-662-04491-9|pages=444))</ref><ref name="Hohl2017">((cite book|author=Alexandre Hohl|title=Testosterone: From Basic to Clinical Aspects|url=https://books.google.com/books?id=Et6TDgAAQBAJ&pg=PA143|date=30 March 2017|publisher=Springer|isbn=978-3-319-46086-4|pages=143,175–177,204–206,229,241,255))</ref><ref name="Hellstrom2012">((cite book|author=Wayne J.G. Hellstrom|title=Androgen Deficiency and Testosterone Replacement: Current Controversies and Strategies|url=https://books.google.com/books?id=F_dNdW10aM0C&pg=PA91|date=28 November 2012|publisher=Springer Science & Business Media|isbn=978-1-62703-179-0|pages=91,129–139))</ref><ref name="Carruthers2006">((cite book|author=Malcolm Carruthers|title=Androgen Deficiency in the Adult Male: Causes, Diagnosis and Treatment|url=https://books.google.com/books?id=YFYgyAEACAAJ|year=2006|publisher=CRC Press|isbn=978-0-367-80018-5|pages=137–178))</ref><ref name="BagatellBremner2003">((cite book|author1=Carrie Bagatell|author2=William J. Bremner|title=Androgens in Health and Disease|url=https://books.google.com/books?id=vDcBCAAAQBAJ&pg=PA146|date=27 May 2003|publisher=Springer Science & Business Media|isbn=978-1-59259-388-0|pages=141–153,200–202,313–334,359,384,403,430–431))</ref><ref name="Llewellyn2011">((cite book|author=William Llewellyn|title=Anabolics|url=https://books.google.com/books?id=afKLA-6wW0oC&pg=PA11|year=2011|publisher=Molecular Nutrition Llc|isbn=978-0-9828280-1-4|pages=11,28–33,321,370,385,392,394,397,412,433,506,537,678))</ref><ref name="NieschlagFreischem1982">((cite book|last1=Nieschlag|first1=E.|last2=Freischem|first2=C. W.|chapter=Androgen Therapy in Hypogonadism and Infertility|editor1=J. Bain|editor2=Wolf-Bernhard Schill|editor3=L. Schwarzstein|title=Treatment of Male Infertility|year=1982|pages=103–115|doi=10.1007/978-3-642-68223-0_8|isbn=978-3-642-68223-0))</ref><ref name="Jones2009">((cite book|author=T. Hugh Jones|title=Advances in the Management of Testosterone Deficiency|url=https://books.google.com/books?id=-wOeOf-oR4oC&pg=PA32|year=2009|publisher=Karger Medical and Scientific Publishers|isbn=978-3-8055-8622-1|pages=32–51,140–141,144))</ref><ref name="WeinKavoussi2011">((cite book|author1=Alan J. Wein|author2=Louis R. Kavoussi|author3=Andrew C. Novick|author4=Alan W. Partin, Craig A. Peters|title=Campbell-Walsh Urology|url=https://books.google.com/books?id=W1aeyJD46kIC&pg=PA740|date=28 September 2011|publisher=Elsevier Health Sciences|isbn=1-4557-2298-7|pages=739–740))</ref><ref name="Snyder1984">((cite journal|last1=Snyder|first1=P J|title=Clinical Use of Androgens|journal=Annual Review of Medicine|volume=35|issue=1|year=1984|pages=207–217|issn=0066-4219|doi=10.1146/annurev.me.35.020184.001231))</ref><ref name="Ebadi2007">((cite book|author=Manuchair Ebadi|title=Desk Reference of Clinical Pharmacology|url=https://books.google.com/books?id=ihxyHbnj3qYC&pg=PA434|date=31 October 2007|publisher=CRC Press|isbn=978-1-4200-4744-8|pages=434–))</ref><ref name="Kochakian2012">((cite book|author=Charles D. Kochakian|title=Anabolic-Androgenic Steroids|url=https://books.google.com/books?id=3-LrCAAAQBAJ&pg=PA454|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-66353-6|pages=454–))</ref><ref name="BasariaWahlstrom2001">((cite journal|last1=Basaria|first1=Shehzad|last2=Wahlstrom|first2=Justin T.|last3=Dobs|first3=Adrian S.|title=Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases|journal=The Journal of Clinical Endocrinology & Metabolism|volume=86|issue=11|year=2001|pages=5108–5117|issn=0021-972X|doi=10.1210/jcem.86.11.7983))</ref><ref name="Srinivas-ShankarSharma2009">((cite journal|last1=Srinivas-Shankar|first1=U.|last2=Sharma|first2=D.|title=Testosterone treatment in elderly men|journal=Advances in Therapy|volume=26|issue=1|year=2009|pages=25–39|issn=0741-238X|doi=10.1007/s12325-008-0137-4))</ref><ref name="WangSwerdloff1997">((cite journal|last1=Wang|first1=Christina|last2=Swerdloff|first2=Ronald S.|title=Androgen Replacement Therapy|journal=Annals of Medicine|volume=29|issue=5|year=1997|pages=365–370|issn=0785-3890|doi=10.3109/07853899708999363))</ref><ref name="MoralesLunenfeld2009">((cite journal|last1=Morales|first1=A.|last2=Lunenfeld|first2=B.|title=Androgen replacement therapy in aging men with secondary hypogonadism|journal=The Aging Male|volume=4|issue=3|year=2009|pages=151–162|issn=1368-5538|doi=10.1080/tam.4.3.151.162))</ref><ref name="Srinivas-ShankarWu2006">((cite journal|last1=Srinivas-Shankar|first1=Upendram|last2=Wu|first2=Frederick CW|title=Drug Insight: testosterone preparations|journal=Nature Clinical Practice Urology|volume=3|issue=12|year=2006|pages=653–665|issn=1743-4270|doi=10.1038/ncpuro0650))</ref><ref name="TanBransgrove2015">((cite journal|last1=Tan|first1=Robert S.|last2=Bransgrove|first2=Linda|title=Testosterone replacement therapy|journal=Postgraduate Medicine|volume=103|issue=5|year=2015|pages=247–256|issn=0032-5481|doi=10.3810/pgm.1998.05.491))</ref><ref name="ZitzmannNieschlag2000">((cite journal|last1=Zitzmann|first1=M|last2=Nieschlag|first2=E|title=Hormone substitution in male hypogonadism|journal=Molecular and Cellular Endocrinology|volume=161|issue=1-2|year=2000|pages=73–88|issn=03037207|doi=10.1016/S0303-7207(99)00227-0))</ref><ref name="Kaufman2004">((cite journal|last1=Kaufman|first1=Joel M.|title=Evolution of delivery systems for testosterone administration|journal=Current Sexual Health Reports|volume=1|issue=3|year=2004|pages=109–114|issn=1548-3584|doi=10.1007/s11930-004-0025-0))</ref><ref name="LeichtnamRolland2006">((cite journal|last1=Leichtnam|first1=Marie-Laure|last2=Rolland|first2=Hervé|last3=Wüthrich|first3=Patrick|last4=Guy|first4=Richard H.|title=Testosterone Hormone Replacement Therapy: State-of-the-Art and Emerging Technologies|journal=Pharmaceutical Research|volume=23|issue=6|year=2006|pages=1117–1132|issn=0724-8741|doi=10.1007/s11095-006-0072-5))</ref><ref name="Morales2005">((cite journal|last1=Morales|first1=Alvaro|title=Androgen replacement therapy in the hypogonadal ageing man|journal=Expert Opinion on Pharmacotherapy|volume=4|issue=6|year=2005|pages=911–918|issn=1465-6566|doi=10.1517/14656566.4.6.911))</ref><ref name="ByrneNieschlag2014">((cite journal|last1=Byrne|first1=M. M.|last2=Nieschlag|first2=E.|title=Testosterone replacement therapy in male hypogonadism|journal=Journal of Endocrinological Investigation|volume=26|issue=5|year=2014|pages=481–489|issn=0391-4097|doi=10.1007/BF03345206))</ref><ref name="pmid18225458">((cite journal | vauthors = Yassin AA, Haffejee M | title = Testosterone depot injection in male hypogonadism: a critical appraisal | journal = Clin Interv Aging | volume = 2 | issue = 4 | pages = 577–90 | date = 2007 | pmid = 18225458 | pmc = 2686335 ))</ref><ref name="Nieschlag2015">((cite journal|last1=Nieschlag|first1=Eberhard|title=Current topics in testosterone replacement of hypogonadal men|journal=Best Practice & Research Clinical Endocrinology & Metabolism|volume=29|issue=1|year=2015|pages=77–90|issn=1521690X|doi=10.1016/j.beem.2014.09.008))</ref><ref name="GoorenBunck2004">((cite journal|last1=Gooren|first1=Louis J G|last2=Bunck|first2=Mathijs C M|title=Androgen Replacement Therapy|journal=Drugs|volume=64|issue=17|year=2004|pages=1861–1891|issn=0012-6667|doi=10.2165/00003495-200464170-00002))</ref><ref name="SurampudiSwerdloff2014">((cite journal|last1=Surampudi|first1=Prasanth|last2=Swerdloff|first2=Ronald S|last3=Wang|first3=Christina|title=An update on male hypogonadism therapy|journal=Expert Opinion on Pharmacotherapy|volume=15|issue=9|year=2014|pages=1247–1264|issn=1465-6566|doi=10.1517/14656566.2014.913022))</ref><ref name="BuvatMaggi2013">((cite journal|last1=Buvat|first1=Jacques|last2=Maggi|first2=Mario|last3=Guay|first3=André|last4=Torres|first4=Luiz Otavio|title=Testosterone Deficiency in Men: Systematic Review and Standard Operating Procedures for Diagnosis and Treatment|journal=The Journal of Sexual Medicine|volume=10|issue=1|year=2013|pages=245–284|issn=17436095|doi=10.1111/j.1743-6109.2012.02783.x))</ref><ref name="HafezHafez2009">((cite journal|last1=Hafez|first1=B.|last2=Hafez|first2=E. S. E.|title=Andropause: Endocrinology, Erectile Dysfunction, and Prostate Pathophysiology|journal=Archives of Andrology|volume=50|issue=2|year=2009|pages=45–68|issn=0148-5016|doi=10.1080/aan.50.2.45.68))</ref><ref name="Llahana2019">((cite book|last1=Llahana|first1=Sofia|title=Advanced Practice in Endocrinology Nursing|chapter=Testosterone Therapy in Adult Men with Hypogonadism|year=2019|pages=885–902|doi=10.1007/978-3-319-99817-6_46))</ref><ref name="LunenfeldOettel2009">((cite journal|last1=Lunenfeld|first1=Bruno|last2=Oettel|first2=Michael|title=Therapeutic potential of testosterone gels|journal=Aging Health|volume=5|issue=2|year=2009|pages=227–245|issn=1745-509X|doi=10.2217/ahe.09.6))</ref><ref name="Brotherton1976">((cite book|author=Janet Brotherton|title=Sex Hormone Pharmacology|url=https://books.google.com/books?id=zt5sAAAAMAAJ|year=1976|publisher=Academic Press|isbn=978-0-12-137250-7|pages=18–19,331,336))</ref><ref name="LinErinoff1996">((cite book|author1=Geraline C. Lin|author2=Lynda Erinoff|title=Anabolic Steroid Abuse|url=https://books.google.com/books?id=DXTysiS5ndQC&pg=PA144|date=July 1996|publisher=DIANE Publishing|isbn=978-0-7881-2969-8|pages=144–))</ref></noinclude><includeonly>See template.</includeonly>
|}<!--

--><noinclude>((Documentation|content=
==See also==
* [[Template:Medications and dosages used in hormone therapy for transgender men]]
* [[Template:Androgen replacement therapy formulations and dosages used in women]]
* [[Template:Androgen/anabolic steroid dosages for breast cancer]]
* [[Template:Clinical dosage ranges of oral and injectable androgens and anabolic steroids]]

==References==
((Reflist))
))
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Pages transcluded onto the current version of this page (help):

Androstanolone (edit)
Fluoxymesterone (edit)
Mesterolone (edit)
Metandienone (edit)
Methyltestosterone (edit)
Testosterone (medication) (edit)
Testosterone buciclate (edit)
Testosterone cypionate (edit)
Testosterone enanthate (edit)
Testosterone isobutyrate (edit)
Testosterone phenylacetate (edit)
Testosterone propionate (edit)
Testosterone propionate/testosterone phenylpropionate/testosterone isocaproate/testosterone decanoate (edit)
Testosterone undecanoate (edit)
Template:Abbr (view source) (protected)
Template:Abbrlink (view source) (template editor protected)
Template:Cite book (view source) (protected)
Template:Cite journal (view source) (protected)
Template:Documentation (view source) (template editor protected)
Template:Hlist/styles.css (view source) (protected)
Template:Main other (view source) (protected)
Template:Navbar (view source) (protected)
Template:No self link (view source) (semi-protected)
Template:No selflink (view source) (semi-protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Module:Arguments (view source) (protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Documentation (view source) (template editor protected)
Module:Documentation/config (view source) (template editor protected)
Module:Documentation/styles.css (view source) (template editor protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Redirect (view source) (protected)
Module:String (view source) (protected)

Return to Template:Androgen replacement therapy formulations and dosages used in men.

Retrieved from "https://en.wikipedia.org/wiki/Template:Androgen_replacement_therapy_formulations_and_dosages_used_in_men"